

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2023/232781 A1

(43) International Publication Date
07 December 2023 (07.12.2023)

(51) International Patent Classification:

A61K 38/22 (2006.01) A61K 47/18 (2017.01)
A61K 9/00 (2006.01) A61K 9/08 (2006.01)
A61K 47/02 (2006.01)

(21) International Application Number:

PCT/EP2023/064395

(22) International Filing Date:

30 May 2023 (30.05.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

22176247.9 30 May 2022 (30.05.2022) EP

(71) Applicant: ZEALAND PHARMA A/S [DK/DK]; Sydmarken 11, DK-2860 Søborg (DK).

(72) Inventor: LUNDQVIST, Joakim; c/o Zealand Pharma A/S, Sydmarken 11, DK-2860 Søborg (DK).

(74) Agent: MILTON, Tamara; D Young & Co LLP, 120 Holborn, London EC1N 2DY (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: LIQUID FORMULATIONS OF AMYLIN ANALOGUES

(57) Abstract: The present invention relates to formulations of amylin analogues, and their use, for example, in the treatment of obesity and metabolic disorders such as diabetes. In particular, the present invention relates to stable aqueous liquid formulations of amylin analogues.

WO 2023/232781 A1